Cardio Diagnostics (CDIO) vs KALA BIO (KALA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
KALA BIO is the larger company by market cap ($5.7 million vs $5.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDIO | KALA |
|---|---|---|
| Share price | $1.86 | $0.2966 |
| Market cap | $5.50M | $5.74M |
| 1-day change | -5.58% | -17.61% |
| EPS (TTM) | $-2.91 | $-10.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.91 | $95.50 |
| 52-week low | $0.97 | $0.2915 |
| Distance from 52-week high | -76.49% | -99.69% |
| Average volume | 56.01K | 1.46M |
| Shares outstanding | 2.96M | 19.34M |
| Employees | 15 | 6 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cardio Diagnostics
CDIO stock →Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
Healthcare · Biotechnology · 15 employees
About KALA BIO
KALA stock →KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
Healthcare · Biotechnology · 6 employees
CDIO vs KALA FAQ
Which is bigger, Cardio Diagnostics or KALA BIO?
KALA BIO (KALA) is larger, with a market capitalization of $5.74M compared with $5.50M for Cardio Diagnostics (CDIO).
Are Cardio Diagnostics and KALA BIO in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.